NCT03701607 is a clinical trial of PD-L1 group in Chemotherapy, sponsored by Baodong Qin.

Who is sponsoring NCT03701607?

NCT03701607 is sponsored by Baodong Qin.

What drugs are being tested in NCT03701607?

Interventions in NCT03701607: PD-L1 group.

What condition does NCT03701607 study?

NCT03701607 studies Chemotherapy, Immunotherapy, PD-L1.

Is NCT03701607 still recruiting?

NCT03701607 is currently status unknown. Last updated 10 October 2018.

Last reviewed 2018-10-10 · How we verify

NCT03701607

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Chemotherapy on PD-L1 in NSCLC

Status unknown Last updated 10 October 2018

What this trial tests

trial testing PD-L1 group in Chemotherapy in 30 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
28 February 2019

31 August 2019

Quick facts

Lead sponsor	Baodong Qin
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 September 2018
Primary completion	28 February 2019
Estimated completion	31 August 2019
Sites	1 location across China

Drugs / interventions tested

PD-L1 group

Conditions studied

Chemotherapy — all drugs for Chemotherapy →
Immunotherapy — all drugs for Immunotherapy →
PD-L1 — all drugs for PD-L1 →

Sponsor

Baodong Qin — full company profile →

Who can join

Adults 18 to 75, any sex, with Chemotherapy or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving chemotherapy in advanced NSCLC patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, et al · · 2020 · cited 58× · PMID 32317979 · DOI 10.3389/fphar.2020.00441
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, et al · · 2020 · cited 32× · PMID 32178474 · DOI 10.3390/cancers12030666

Verify or expand the search:

Other recruiting trials for Chemotherapy

Currently open trials in the same condition.

NCT07435597 — Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients · NA · recruiting
NCT07218874 — Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application · NA · recruiting
NCT07339488 — Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal · Phase 2 · active not recruiting
NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting
NCT06999616 — Physical Activity in Cancer Patients in an Oncology Day Clinic - Implementing a Person-centered Program Led by Nurses · recruiting

Other Baodong Qin trials

Trials by the same sponsor.

NCT04116918 — Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC · unknown
NCT03683407 — Effect of Chemotherapy on TMB in NSCLC · unknown
NCT03239015 — Efficacy and Safety of Precision Therapy in Refractory Tumor · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03701607 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baodong Qin
Last refreshed: 10 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03701607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing